ES2421708T3 - Resolución enantiomérica de nucleósidos de 1,3-oxatiolano 2,4-disustituidos - Google Patents

Resolución enantiomérica de nucleósidos de 1,3-oxatiolano 2,4-disustituidos

Info

Publication number
ES2421708T3
ES2421708T3 ES08789129T ES08789129T ES2421708T3 ES 2421708 T3 ES2421708 T3 ES 2421708T3 ES 08789129 T ES08789129 T ES 08789129T ES 08789129 T ES08789129 T ES 08789129T ES 2421708 T3 ES2421708 T3 ES 2421708T3
Authority
ES
Spain
Prior art keywords
ester
salt
compound
mixture
racemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08789129T
Other languages
English (en)
Inventor
Dragos Vizitiu
Jean-Eric Lacoste
Dan Simion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Application granted granted Critical
Publication of ES2421708T3 publication Critical patent/ES2421708T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un procedimiento para la preparación de enantiómeros únicos de un compuesto de fórmula (B), en cualquiera delas configuraciones cis o trans , o una sal o éster farmacéuticamente aceptable del mismo, comprendiendo dichoprocedimiento: en donde R1 es base de pirimidina o un derivado farmacéuticamente aceptable de la misma; R2 es hidrógeno, -C(O)-R3, o junto con el átomo de oxígeno al que está unido forma un éster derivado de unácido polifuncional; y R3 es hidrógeno, alquilo de cadena lineal o ramificada, alcoxialquilo, aralquilo, ariloxialquilo, arilo,dihidropiridinilo sustituido, un éster de sulfonato, un éster de sulfato, un éster de aminoácido, ésteres demono, di- o tri-fosfatos; comprendiendo dicho procedimiento formar una sal conglomerado de mezclaracémica o una mezcla enriquecida enantioméricamente de un compuesto de fórmula (B) con un ácido, endonde la sal conglomerado resultante tiene las siguientes características: el espectro IR de la sal del compuesto racémico, una mezcla 1:1 de cristales (-) y (+), es idéntico alde cada uno de los enantiómeros únicos, y la sal del compuesto racémico tiene un punto de fusiónmás bajo que el de cada enantiómero único; y resolver dicha mezcla por cristalización.
ES08789129T 2008-09-05 2008-09-05 Resolución enantiomérica de nucleósidos de 1,3-oxatiolano 2,4-disustituidos Active ES2421708T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002314 WO2010026439A1 (en) 2008-09-05 2008-09-05 Enantiomeric resolution of 2,4-disubstituted 1,3-oxathiolane nucleosides

Publications (1)

Publication Number Publication Date
ES2421708T3 true ES2421708T3 (es) 2013-09-05

Family

ID=40525277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08789129T Active ES2421708T3 (es) 2008-09-05 2008-09-05 Resolución enantiomérica de nucleósidos de 1,3-oxatiolano 2,4-disustituidos

Country Status (16)

Country Link
US (1) US20120184739A1 (es)
EP (1) EP2346890B1 (es)
JP (1) JP5690731B2 (es)
KR (1) KR101556815B1 (es)
CN (1) CN102203111B (es)
AU (1) AU2008361409B2 (es)
BR (1) BRPI0823087A2 (es)
CA (1) CA2736163C (es)
DK (1) DK2346890T3 (es)
ES (1) ES2421708T3 (es)
HK (1) HK1159641A1 (es)
MX (1) MX2011002507A (es)
NZ (1) NZ591709A (es)
PT (1) PT2346890E (es)
WO (1) WO2010026439A1 (es)
ZA (1) ZA201101910B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196107A1 (zh) * 2018-04-13 2019-10-17 深圳达闼科技控股有限公司 物质成分的检测方法及相关装置和计算机可读存储介质

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587480A (en) 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US7968703B2 (en) 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
ZA201101910B (en) 2011-12-28
KR20110091646A (ko) 2011-08-12
HK1159641A1 (es) 2012-08-03
NZ591709A (en) 2012-11-30
EP2346890A1 (en) 2011-07-27
EP2346890B1 (en) 2013-03-20
CA2736163A1 (en) 2010-03-11
CN102203111A (zh) 2011-09-28
DK2346890T3 (da) 2013-06-24
US20120184739A1 (en) 2012-07-19
JP5690731B2 (ja) 2015-03-25
MX2011002507A (es) 2011-07-29
KR101556815B1 (ko) 2015-10-01
AU2008361409A1 (en) 2010-03-11
CN102203111B (zh) 2014-08-20
BRPI0823087A2 (pt) 2015-06-16
JP2012502016A (ja) 2012-01-26
AU2008361409B2 (en) 2015-02-12
CA2736163C (en) 2016-08-02
WO2010026439A1 (en) 2010-03-11
PT2346890E (pt) 2013-06-27

Similar Documents

Publication Publication Date Title
AR059916A1 (es) Procesos y productos intermedios para preparar compuestos esterico
AR061924A1 (es) Proceso para elaborar 2- amino -5 - halobenzamidas 3- sustituidas
AR059010A1 (es) 6-( aril polisustituido )-4- aminopicolinatos y su uso como herbicidas
PE20120027A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20161443A1 (es) Compuestos
MX2013013857A (es) Compuestos insecticidas.
ATE537136T1 (de) Neues verfahren zur herstellung von säurechloriden
EA201190237A1 (ru) Аналоги изоксазол-3(2н)-она в качестве терапевтических агентов
HN2009000157A (es) Profarmacos de compuesto de cinamida
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
HRP20080510T3 (en) Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
IN2014MN01521A (es)
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
AR052870A1 (es) Sintesis de analogos de himbacina
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
EA201891769A1 (ru) СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
RS53909B1 (en) 5- (Phenyl / pyridinyl-ethynyl) -2-pyridine / 2-pyrimidine carboxamides as modulators of MGLUR5
RS53353B (en) NEW PROCEDURES FOR THE PRODUCTION OF BENZOPHENONE DERIVATIVES